<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428944</url>
  </required_header>
  <id_info>
    <org_study_id>MP-33-2021-2805</org_study_id>
    <nct_id>NCT04428944</nct_id>
  </id_info>
  <brief_title>STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation</brief_title>
  <acronym>STARAF3</acronym>
  <official_title>Strategies for Catheter Ablation of Persistent Atrial Fibrillation: a Randomized, Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy of three different ablation strategies
      in patients with persistent AF:

        1. PV antral isolation alone (PVAI)

        2. PV antral isolation plus ablation of drivers (PVAI+drivers)

        3. PV antral isolation plus isolation of posterior wall (PVAI+box) All three strategies
           will employ contemporary catheter ablation technology using more efficient open
           irrigated tip cooling and contact force sensing.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from documented atrial arrhythmia ≥ 30 seconds at 18 months after one ablation procedure on or off antiarrhythmic medications (AAM).</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented AF &gt; 30 seconds at 18 months after one procedure on or off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented AF &gt; 30 seconds at 18 months after one or more procedures on or off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented atrial arrhythmia &gt; 30 seconds at 18 months after one or more procedures on or off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented AF &gt; 30 seconds at 18 months after one procedure off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented atrial arrhythmia &gt; 30 seconds at 18 months after one procedure off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented AF &gt; 30 seconds at 18 months after one or more procedures off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented atrial arrhythmia &gt; 30 seconds after one or more procedures off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented symptomatic AF &gt; 30 seconds at 18 months after one procedure on or off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented symptomatic atrial arrhythmia &gt; 30 seconds after one procedure on or off AAM</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Each of the above success measures stratified by CHA2DS2-VASc score</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of peri-procedural complications including stroke, PV stenosis, cardiac perforation, esophageal injury, phrenic nerve palsy, and death</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure duration</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time (dose)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiofrequency time</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of repeat procedures</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of each strategy on AF cycle length changes and AF termination</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of acute AF termination on long-term procedural outcome</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measurements during follow-up using AFEQT questionnaire</measure>
    <time_frame>6-12-18 months</time_frame>
    <description>AFEQT questionnaires will be used at baseline, 6, 12 and 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measurements during follow-up using SF36 questionnaires</measure>
    <time_frame>6-12-18 months</time_frame>
    <description>SF36 questionnaires will be used at baseline, 6, 12 and 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AF burden post-ablation procedure (% of time in AF)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>PV antral isolation alone (PVAI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PV antral isolation alone (PVAI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PV antral isolation plus ablation of drivers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PV antral isolation plus ablation of drivers (PVAI+drivers)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PV antral isolation plus isolation of posterior wall</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PV antral isolation plus isolation of LA posterior wall (PVAI+Box)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI)</intervention_name>
    <description>Standard PVI</description>
    <arm_group_label>PV antral isolation alone (PVAI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)</intervention_name>
    <description>Standard PVI + Ablation of drivers in LA and RA</description>
    <arm_group_label>PV antral isolation plus ablation of drivers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)</intervention_name>
    <description>Standard PVI + Electrical isolation of the posterior wall of the left atrium</description>
    <arm_group_label>PV antral isolation plus isolation of posterior wall</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years of age or older

          2. Patients undergoing first-time ablation procedure for AF

          3. Patients with persistent AF defined as a sustained episode more than 3 months but less
             than three years

          4. Patients with symptomatic AF - symptomatic patients are those who have been aware of
             their AF at any time within the last 5 years prior to enrolment. Symptoms may include,
             but are not restricted to, palpitations, shortness of breath, chest pain, fatigue,
             left ventricular dysfunction, or other symptoms or any combination of the above

          5. Patients whose AF has been refractory to at least one antiarrhythmic drug

          6. At least one episode of AF must have been documented by ECG, holter, loop recorder,
             telemetry, trans-telephonic monitor or implanted device within the last 2 years from
             enrolment

          7. Patients must be able and willing to provide written informed consent to participate
             in the study

        Exclusion Criteria:

          1. Patients with paroxysmal AF (no episodes lasting &gt; 7 days)

          2. Patients with early persistent AF, sustained episode ≤ 3 months

          3. Patients with very long lasting persistent AF (episodes lasting &gt; 3 years)

          4. Patients with CHA2DS2-VASc score of 0.

          5. Patients for whom cardioversion or sinus rhythm will never be attempted/pursued

          6. Patients with AF felt to be secondary to an obvious reversible cause

          7. Patients with contraindication to oral anticoagulation or systemic anticoagulation
             with heparin

          8. Patients with left atrial diameter &gt; 60 mm in the parasternal long axis view

          9. Patients who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atul Verma, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southlake Regional Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Macle, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Morello</last_name>
    <phone>514-376-3330</phone>
    <phone_ext>6279</phone_ext>
    <email>mary.morello@icm-mhi.org</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montreal Heart Institute</investigator_affiliation>
    <investigator_full_name>Laurent Macle</investigator_full_name>
    <investigator_title>Cardiologist electrophysiologist</investigator_title>
  </responsible_party>
  <keyword>ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

